Keck School Faculty

Diane Marie Da Silva, PhD, MS
Diane Marie Da Silva, PhD, MS
Assistant Professor of Research Obstetrics & Gynecology
Obstetrics & Gynecology
NRT 7517 Health Sciences Campus Los Angeles
Dr. Da Silva's current research interests span multiple areas of study that include applying immune modulation strategies to enhance natural and vaccine-induced immunity against solid tumors, investigating the molecular and cellular determinants in the tumor microenvironment that lead to cancer development, progression and metastasis, and assessing the clinical significance of the cervico-vaginal microbiota in relation to gynecologic cancer development, progression and response to treatment.

Dr. Da Silva has broad expertise and skills associated with immunology, oncology and infectious disease research, immunotherapeutics, vaccine immunogenicity and efficacy, pre-clinical vaccine/adjuvant development, small animal syngeneic and xenograft tumor models, clinical translational research, and analysis of immune responses and biomarkers in human clinical samples for many different types of cancer. Dr. Da Silva is the Technical Director of the Norris Comprehensive Cancer Center Beckman Center for Immune Monitoring, a core resource for collecting, processing and analyzing human clinical trial samples to discover and validate immune-related biomarkers of response to cancer therapies. She has spent the past 15 years studying human papillomavirus (HPV) interactions with host immune cell receptors and immune escape mechanisms used by HPV, and has been involved with development of therapeutic vaccine strategies against HPV-induced cancers.

Since 2015, Dr. Da Silva is the course director for the undergraduate Introductory course in Modern Oncology and Cancer Biology for the USC Minor in Health Care Studies.

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer JAMA Oncol. 2019 Nov 27. . View in PubMed

Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease Vaccine. 2019 05 16; 37(22):2915-2924. . View in PubMed

Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study BMC Cancer. 2018 Oct 11; 18(1):970. . View in PubMed

Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors Gynecol Oncol. 2018 10; 151(1):102-110. . View in PubMed

Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses Cancer Immunol Res. 2018 07; 6(7):870-880. . View in PubMed

Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response PLoS One. 2018; 13(1):e0191311. . View in PubMed

Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation Sci Rep. 2018 08 03; 8(1):11642. . View in PubMed

Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection J Gen Virol. 2016 Feb; 97(2):422-434. . View in PubMed

T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation Papillomavirus Res. 2016 12; 2:21-30. . View in PubMed

Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment AIDS Patient Care STDS. 2016 07; 30(7):291-306. . View in PubMed

Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells J Interferon Cytokine Res. 2016 05; 36(5):291-301. . View in PubMed

Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients J Acquir Immune Defic Syndr. 2016 09 01; 73(1):27-33. . View in PubMed

Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro Virol J. 2016 11 18; 13(1):187. . View in PubMed

Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases Hum Vaccin Immunother. 2016 06 02; 12(6):1418-29. . View in PubMed

Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C Papillomavirus Res. 2015 Dec 01; 1:12-21. . View in PubMed

Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C Clin Immunol. 2015 Dec; 161(2):197-208. . View in PubMed

A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours J Gen Virol. 2015 Sep; 96(9):2764-2768. . View in PubMed

Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes Prostate. 2015 Feb 15; 75(3):280-91. . View in PubMed

Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection J Antimicrob Chemother. 2015; 70(6):1686-90. . View in PubMed

Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression J Immunol. 2014 May 15; 192(10):4748-57. . View in PubMed

Suppression of Langerhans cell activation is conserved amongst human papillomavirus a and ß genotypes, but not a µ genotype Virology. 2014 Mar; 452-453:279-86. . View in PubMed

The evolving field of human papillomavirus receptor research: a review of binding and entry J Virol. 2013 Jun; 87(11):6062-72. . View in PubMed

The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection PLoS One. 2012; 7(8):e43519. . View in PubMed

Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression Cancer Res. 2010 May 15; 70(10):3955-64. . View in PubMed

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508 Cancer. 2010 Jan 15; 116(2):424-31. . View in PubMed

A major role for the minor capsid protein of human papillomavirus type 16 in immune escape J Immunol. 2009 Nov 15; 183(10):6151-6. . View in PubMed

Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors Clin Cancer Res. 2009 Oct 01; 15(19):6167-76. . View in PubMed

Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16 J Immunol. 2009 Mar 01; 182(5):2919-28. . View in PubMed

Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines Cancer Immun. 2008 Apr 24; 8:8. . View in PubMed

Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions Int J Cancer. 2008 Jan 15; 122(2):247-59. . View in PubMed

Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity J Immunol. 2007 Jun 15; 178(12):7587-97. . View in PubMed

Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro Hum Immunol. 2005 Jul; 66(7):762-72. . View in PubMed

Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation J Immunol. 2005 Jun 01; 174(11):7172-8. . View in PubMed

Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells Vaccine. 2005 Feb 25; 23(14):1720-9. . View in PubMed

Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells Cancer Res. 2003 Jul 01; 63(13):3478-82. . View in PubMed

Cervical cancer vaccines: recent advances in HPV research Viral Immunol. 2003; 16(2):111-21. . View in PubMed

Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses J Immunol. 2002 Sep 15; 169(6):3242-9. . View in PubMed

Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention Intervirology. 2002; 45(4-6):300-7. . View in PubMed

Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines Virology. 2001 Nov 25; 290(2):350-60. . View in PubMed

Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro J Immunol. 2001 May 15; 166(10):5917-24. . View in PubMed

Physical interaction of human papillomavirus virus-like particles with immune cells Int Immunol. 2001 May; 13(5):633-41. . View in PubMed

A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy Clin Cancer Res. 2001 Mar; 7(3 Suppl):876s-881s. . View in PubMed

Cervical cancer vaccines: emerging concepts and developments J Cell Physiol. 2001 Feb; 186(2):169-82. . View in PubMed

Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response J Cell Biochem. 1999 May 01; 73(2):145-52. . View in PubMed

Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles Biol Chem. 1999 Mar; 380(3):335-40. . View in PubMed

Papillomavirus virus-like particles as anticancer vaccines Curr Opin Mol Ther. 1999 Feb; 1(1):82-8. . View in PubMed

Powered by SC CTSI
Go to Top